Stanford Cancer Institute

Cancer Cell Therapy

Multiple Myeloma

Post-Auto

CCT5054
Phase II T Cell Therapy in MM w/Sub-Optimal Response After Autologous HCT & Maintenance Lenalidomide
Pl: Sidana
Sponsor: Pending

CCT5025
Phase III bb2121 vs SoC Triple Regimens in Relapsed & Refractory Multiple Myeloma (RRMM) (KarMMa-3)
Pl: Liedtke
Sponsor: Celgene Corporation Priority 5

CCT5030
Phase I ALLO-715 Eval Anti-BCMA Allogeneic CAR T Cell Tx in Relapsed/Refractory Multiple Myeloma
Pl: Liedtke
Sponsor: Allogene Therapeutics Priority 2

CCT5057
Phase I/II ALLO-647 and ALLO-605, an Anti-BCMA Allogeneic CAR T Cell Therapy in Relapsed / Refractory Multiple Myeloma
Pl: Sidana
Sponsor: Allogene Therapeutics Priority 1

CCT5056
Expanded Access Protocol (EAP) in Idecabtagene Vicleucel that is Nonconforming for Commercial Release
Pl: Sidana
Sponsor: Pending

CCT5059
Safety and Efficacy Study of JNJ-68284528 (Ciltacabtagene Autoleucel) Out of Specification (OOS) for Commercial Release in Patients with Multiple Myeloma
Pl: Sidana
Sponsor: Janssen Scientific Affairs, LLC

CCT5062
A Phase III Randomized study Comparing VRd Followed by Ciltacabtagene Autoleucel Therapy Directed Against VRd followed by Rd Therapy in Newly Diagnosed Multiple Myeloma
Pl: Sidana
Sponsor: Janssen Scientific Affairs, LLC

Relapsed

Patients with >= 2 prior lines of Therapy

Patients with >= 3 prior lines of Therapy

Patients with 1-3 prior lines of Therapy

Auto

CCT5052
Phase III Relapsed Myeloma (RRMM) (KarMMa-3)
Pl: Liedtke
Sponsor: Celgene Corporation Priority 5

KEY

- Pending
- Open for Enrollment
- Link
- Optional Path
- Trial Posting
- Extension Study
- Immunotherapy
- Enrollment on Hold